Evidence map›Paper›PMID 17191140›Full record

ArticleNeurochemical research2007

Cyclic GMP-dependent pathways protect differentiated oligodendrocytes from multiple types of injury.

Joyce A Benjamins, Liljana Nedelkoska

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Mechanisms Involved in the Remyelinating Effect of Sildenafil.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2018
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Joyce A BenjaminsDepartment of Neurology, Wayne State University School of Medicine, 1228 Elliman Building, 421 E. Canfield Avenue, Detroit, MI 48201, USA. joyce.benjamins@wayne.edu
Liljana Nedelkoska
Wayne State University · US

Funding

MYELINATION: ASSEMBLY OF LIPIDS &PROTEINSR01NS013143 · NINDS · WAYNE STATE UNIVERSITY · PI BENJAMINS, JOYCE A · 1985 to 2003
$1.0M
NINDS NIH HHS NS13143
6 · The paper itself

Abstract

The cyclic GMP analog 8-bromo-cyclic GMP (8-Br-cGMP) protects differentiated murine oligodendrocytes (OLs) from caspase-mediated death initiated by staurosporine, thapsigargin or kainate. Caspase-independent death caused by high levels of NO is also partially prevented by 8-Br-cGMP. Inhibitors of protein kinase G (cGMP-dependent protein kinase, cGK) reversed protection, supporting involvement of cGK. Since NO stimulates soluble guanylate cyclase, increasing cGMP, we treated OLs with low levels of NO and observed partial protection against thapsigargin, staurosporine and kainate. Two inhibitors of mitochondrial pore transition (MPT), cyclosporin A and bongkrekic acid, were poorly protective, indicating that cGMP is not acting primarily by blocking MPT. 8Br-cGMP was more effective than 8Br-cAMP in protecting against staurosporine or release of intracellular Ca(++) by thapsigargin. The cAMP analog exhibited little or no protection against kainate or high levels of NO. Thus cGK signaling is more effective than protein kinase A or phosphodiesterase 3 signaling in preventing OL death.

Indexed as

8-Bromo Cyclic Adenosine MonophosphateAnimalsBongkrekic AcidCell DeathCell DifferentiationCells, CulturedCyclic GMPCyclic GMP-Dependent Protein KinasesCyclosporineKainic AcidMiceMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PoreNitric OxideNitroso CompoundsOligodendroglia8-Bromo Cyclic Adenosine Monophosphate8-bromocyclic GMPBongkrekic AcidCyclic GMPCyclic GMP-Dependent Protein KinasesCyclosporineKainic AcidMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PoreNitric OxideNitroso CompoundsNOC 12S-Nitroso-N-AcetylpenicillamineStaurosporineThapsigargin

Identifiers

PMID17191140
OpenAlexW2051818172

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.